News Digest / Ticker: CVKD

Ticker: CVKD

07:03am, Monday, Aug 11, 2025

Cadrenal pushes tecarfarin into ESKD trials as cash burn, rising G&A heighten financing risk

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) - Quick internal read Management is advancing tecarfarin into late-stage clinical activity (announced trial plans for ESKD patients on August 5, 2025) while burning cash to support operations and public-company overhead. The company used its ATM program ...

07:04am, Thursday, May 08, 2025

Cadrenal Therapeutics Reports Increased Losses Amid Ongoing Operations and Funding Activities in Q1 2025